The chi-squared test and the t-test for binary and continuous outcomes

The chi-squared test and the t-test for binary and continuous outcomes respectively. doi:10.1371/journal.pone.0046909.tText Messages for Adherence in HIVTable 3. Outcomes at 3 months.Effect Estimatem RR (95 CI);p 0.77(0.63,0.94);0.029 0.97(0.85,1.10);0.622 MD (95 CI);p 0.10 (20.03,0.23);0.139 RR (95 CI);p 0.61(0.32,1.14);0.094 1.19 (0.82,1.74);0.353 Not estimable 0.99(0.88,1.12); 0.893 MD (95 CI);p 20.30 (23.81,3.21);0.866 0.17 (20.98,1.32);0.771 31 (232.5,94.5); 0.337 20.20(20.19,0.15);0.Outcome PrimaryType Binary VAS.95 Self report (no missed doses) Continuous Pharmacy Refill DataSMS group (n = 101) n ( ) 52(51.5) 82 (81.2) Mean (SD) 2.3(0.50) n ( ) 60(59.4) 39(38.6) 0 85(84.2) Mean (SD) 70.9(12.18) 26.24(4.087) 406 (230) 3.67 (0.623)Control group (n = 99) n ( ) 66(66.7) 83(83.8) Mean (SD) 2.2 (0.45) n ( ) 70(70.7) 32(32.3) 0 84(84.8) Mean (SD) 71.2(12.96) 26.07(4.175) 375 (225) 3.69 (0.615)Secondary*?Binary VAS.90 Presence of a new OI Mortality Retention Continuous Weight (kg) BMI CD4 (cells per mm3): Quality of life (SF-12 scale score)(SMS: short message service; RR: risk ratio; CI: confidence interval; SD: standard deviation; MD: mean difference; VAS: visual analogue scale; BMI: body mass index; OI: opportunistic infection; CD4: CD4-positive-T-lymphocyte; SF: short form). *Bonferroni adjustment for secondary outcomes: 0.05/8 = 0.006. ?Insufficient data for viral load (n = 0). m P-values obtained using the chi-squared test and the t-test for binary and continuous outcomes respectively. doi:10.1371/journal.pone.0046909.tweekly messages like the Kenyan trials, but did not observe any Epigenetics significant benefits. Both Kenyan trials ran for up to one year, while our trial ended at 6 months. The duration of our trial might not have been sufficient to observe a significant effect. Another important difference is the fact that both Kenyan trials enrolled participants who had recently initiated ART [8,9]. The Epigenetics median duration on ART at baseline in this study was 31 and 22 Table 4. Satisfaction with the text message among the participants who received text messages (n = 101).Question How would you rate the text message? Excellent Very good Good Average Bad Very bad Did it help you remember to take your medication? Yes No Do you want to continue receiving text messages? Yes No Would you recommend it to a friend? Yes No *Percentages may not add up to 100 due to rounding off. doi:10.1371/journal.pone.0046909.tCount ( )*12 (11.8) 30 (29.7) 21(20.8) 17 (16.8) 5 (4.9) 16 (15.8)92 (91.1) 9 (8.66 (65.3) 35 (34.7)82 (81.2) 19 (18.8)months for the intervention and control groups respectively. This may also explain the negative results, since duration on ART has been shown to have negative effects on adherence to ART in Cameroon [26]. We speculate that the SMS may be more effective ?in treatment-naive populations. While the risk of disclosure of status has 23388095 title=’View abstract’ target=’resource_window’>15755315 been mentioned in some studies [27], this is the first study documenting a case of withdrawal for privacy reasons. In Cameroon, there is still a lot of stigma associated with HIV, and it is a known cause of poor adherence [28]. Although we did not include the term “HIV” in the content of the text messages, we did include “medications” and gave a clinic number which could arouse suspicion by non-participants reading the message. Interestingly, we had a very high proportion of clients in this study who reported having disclosed their status to their families. This may have reflected a selection bias fo.The chi-squared test and the t-test for binary and continuous outcomes respectively. doi:10.1371/journal.pone.0046909.tText Messages for Adherence in HIVTable 3. Outcomes at 3 months.Effect Estimatem RR (95 CI);p 0.77(0.63,0.94);0.029 0.97(0.85,1.10);0.622 MD (95 CI);p 0.10 (20.03,0.23);0.139 RR (95 CI);p 0.61(0.32,1.14);0.094 1.19 (0.82,1.74);0.353 Not estimable 0.99(0.88,1.12); 0.893 MD (95 CI);p 20.30 (23.81,3.21);0.866 0.17 (20.98,1.32);0.771 31 (232.5,94.5); 0.337 20.20(20.19,0.15);0.Outcome PrimaryType Binary VAS.95 Self report (no missed doses) Continuous Pharmacy Refill DataSMS group (n = 101) n ( ) 52(51.5) 82 (81.2) Mean (SD) 2.3(0.50) n ( ) 60(59.4) 39(38.6) 0 85(84.2) Mean (SD) 70.9(12.18) 26.24(4.087) 406 (230) 3.67 (0.623)Control group (n = 99) n ( ) 66(66.7) 83(83.8) Mean (SD) 2.2 (0.45) n ( ) 70(70.7) 32(32.3) 0 84(84.8) Mean (SD) 71.2(12.96) 26.07(4.175) 375 (225) 3.69 (0.615)Secondary*?Binary VAS.90 Presence of a new OI Mortality Retention Continuous Weight (kg) BMI CD4 (cells per mm3): Quality of life (SF-12 scale score)(SMS: short message service; RR: risk ratio; CI: confidence interval; SD: standard deviation; MD: mean difference; VAS: visual analogue scale; BMI: body mass index; OI: opportunistic infection; CD4: CD4-positive-T-lymphocyte; SF: short form). *Bonferroni adjustment for secondary outcomes: 0.05/8 = 0.006. ?Insufficient data for viral load (n = 0). m P-values obtained using the chi-squared test and the t-test for binary and continuous outcomes respectively. doi:10.1371/journal.pone.0046909.tweekly messages like the Kenyan trials, but did not observe any significant benefits. Both Kenyan trials ran for up to one year, while our trial ended at 6 months. The duration of our trial might not have been sufficient to observe a significant effect. Another important difference is the fact that both Kenyan trials enrolled participants who had recently initiated ART [8,9]. The median duration on ART at baseline in this study was 31 and 22 Table 4. Satisfaction with the text message among the participants who received text messages (n = 101).Question How would you rate the text message? Excellent Very good Good Average Bad Very bad Did it help you remember to take your medication? Yes No Do you want to continue receiving text messages? Yes No Would you recommend it to a friend? Yes No *Percentages may not add up to 100 due to rounding off. doi:10.1371/journal.pone.0046909.tCount ( )*12 (11.8) 30 (29.7) 21(20.8) 17 (16.8) 5 (4.9) 16 (15.8)92 (91.1) 9 (8.66 (65.3) 35 (34.7)82 (81.2) 19 (18.8)months for the intervention and control groups respectively. This may also explain the negative results, since duration on ART has been shown to have negative effects on adherence to ART in Cameroon [26]. We speculate that the SMS may be more effective ?in treatment-naive populations. While the risk of disclosure of status has 23388095 title=’View abstract’ target=’resource_window’>15755315 been mentioned in some studies [27], this is the first study documenting a case of withdrawal for privacy reasons. In Cameroon, there is still a lot of stigma associated with HIV, and it is a known cause of poor adherence [28]. Although we did not include the term “HIV” in the content of the text messages, we did include “medications” and gave a clinic number which could arouse suspicion by non-participants reading the message. Interestingly, we had a very high proportion of clients in this study who reported having disclosed their status to their families. This may have reflected a selection bias fo.